Ultrastructural study of methionine sulfoximine induced Alzheimer type II astrocytosis

J. A. Gutierrez, Michael D Norenberg

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Because methionine sulfoximine (MSO), unlike most convulsant drugs, has a long latent period, it can be used to study changes in the brain before the occurrence of seizures. A previous light microscopic study during the preictal period following MSO revealed the development of an Alzheimer type II astrocyte change as the principal morphologic alteration. This ultrastructural study of the brain cortex was performed in rats during the preictal period following MSO administration. The morphologic changes were restricted to the astrocytes and consisted of cytoplasmic enlargement, mitochondrial and rough endoplasmic reticulum proliferation, accumulation of glycogen, development of cisternal and saccular smooth endoplasmic reticulum, nuclear chromatin clumping, and hydropic degenerative changes. These findings resemble those seen in experimental ammonia encephalopathy, suggesting an important role of ammonia in the evolution of the morphologic changes described. The findings, moreover, suggest that the primary effect of MSO is on astrocytes and that astrocytic abnormalities play a role in the development of MSO-induced seizures.

Original languageEnglish
Pages (from-to)285-300
Number of pages16
JournalAmerican Journal of Pathology
Volume86
Issue number2
StatePublished - Dec 1 1977
Externally publishedYes

Fingerprint

Methionine Sulfoximine
Gliosis
Astrocytes
Ammonia
Seizures
Convulsants
Smooth Endoplasmic Reticulum
Rough Endoplasmic Reticulum
Brain
Brain Diseases
Glycogen
Chromatin
Edema
Light
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Ultrastructural study of methionine sulfoximine induced Alzheimer type II astrocytosis. / Gutierrez, J. A.; Norenberg, Michael D.

In: American Journal of Pathology, Vol. 86, No. 2, 01.12.1977, p. 285-300.

Research output: Contribution to journalArticle

@article{07a52a36b7304cf1ad1730db16a8521d,
title = "Ultrastructural study of methionine sulfoximine induced Alzheimer type II astrocytosis",
abstract = "Because methionine sulfoximine (MSO), unlike most convulsant drugs, has a long latent period, it can be used to study changes in the brain before the occurrence of seizures. A previous light microscopic study during the preictal period following MSO revealed the development of an Alzheimer type II astrocyte change as the principal morphologic alteration. This ultrastructural study of the brain cortex was performed in rats during the preictal period following MSO administration. The morphologic changes were restricted to the astrocytes and consisted of cytoplasmic enlargement, mitochondrial and rough endoplasmic reticulum proliferation, accumulation of glycogen, development of cisternal and saccular smooth endoplasmic reticulum, nuclear chromatin clumping, and hydropic degenerative changes. These findings resemble those seen in experimental ammonia encephalopathy, suggesting an important role of ammonia in the evolution of the morphologic changes described. The findings, moreover, suggest that the primary effect of MSO is on astrocytes and that astrocytic abnormalities play a role in the development of MSO-induced seizures.",
author = "Gutierrez, {J. A.} and Norenberg, {Michael D}",
year = "1977",
month = "12",
day = "1",
language = "English",
volume = "86",
pages = "285--300",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Ultrastructural study of methionine sulfoximine induced Alzheimer type II astrocytosis

AU - Gutierrez, J. A.

AU - Norenberg, Michael D

PY - 1977/12/1

Y1 - 1977/12/1

N2 - Because methionine sulfoximine (MSO), unlike most convulsant drugs, has a long latent period, it can be used to study changes in the brain before the occurrence of seizures. A previous light microscopic study during the preictal period following MSO revealed the development of an Alzheimer type II astrocyte change as the principal morphologic alteration. This ultrastructural study of the brain cortex was performed in rats during the preictal period following MSO administration. The morphologic changes were restricted to the astrocytes and consisted of cytoplasmic enlargement, mitochondrial and rough endoplasmic reticulum proliferation, accumulation of glycogen, development of cisternal and saccular smooth endoplasmic reticulum, nuclear chromatin clumping, and hydropic degenerative changes. These findings resemble those seen in experimental ammonia encephalopathy, suggesting an important role of ammonia in the evolution of the morphologic changes described. The findings, moreover, suggest that the primary effect of MSO is on astrocytes and that astrocytic abnormalities play a role in the development of MSO-induced seizures.

AB - Because methionine sulfoximine (MSO), unlike most convulsant drugs, has a long latent period, it can be used to study changes in the brain before the occurrence of seizures. A previous light microscopic study during the preictal period following MSO revealed the development of an Alzheimer type II astrocyte change as the principal morphologic alteration. This ultrastructural study of the brain cortex was performed in rats during the preictal period following MSO administration. The morphologic changes were restricted to the astrocytes and consisted of cytoplasmic enlargement, mitochondrial and rough endoplasmic reticulum proliferation, accumulation of glycogen, development of cisternal and saccular smooth endoplasmic reticulum, nuclear chromatin clumping, and hydropic degenerative changes. These findings resemble those seen in experimental ammonia encephalopathy, suggesting an important role of ammonia in the evolution of the morphologic changes described. The findings, moreover, suggest that the primary effect of MSO is on astrocytes and that astrocytic abnormalities play a role in the development of MSO-induced seizures.

UR - http://www.scopus.com/inward/record.url?scp=0017579115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017579115&partnerID=8YFLogxK

M3 - Article

C2 - 556886

AN - SCOPUS:0017579115

VL - 86

SP - 285

EP - 300

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 2

ER -